Abstract
Persistently detectable serum thyroglobulin (Tg) without residual normal thyroid after a total thyroidectomy for papillary thyroid carcinoma (PTC) indicates biochemically persistent disease, even in patients without detectable lesions on imaging studies. Increasing serum Tg levels reflect progression of the disease. For distant organ metastases, radioactive iodine (RAI) therapy followed by thyroid-stimulating hormone (TSH) suppression is the first-line treatment. Several molecular-targeted agents appeared recently as a new modality for RAI-refractory metastases. However, it is difficult to decide whether and when such agents should be administered in individual patients. The evaluation of the tumor volume and progressiveness of the disease is important in making this treatment decision. A short Tg-doubling time (Tg-DT) is a very strong predictor of both carcinoma recurrence and carcinoma-related death superior to the conventional factors. Patients with a Tg-DT <1 year are likely to die of carcinoma, while metastases are not immediately life-threatening for those with a Tg-DT >2 years. We must carefully weigh the advantages and disadvantages of using molecular-targeted agents, because they usually are associated with severe adverse events. Shortening of Tg-DT over time may occur, which suggests appearance of more aggressive metastasis or aggressive change of the tumor nature.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Airtight tracheocutaneostomy after window resection of the trachea for invasive papillary thyroid carcinoma: experience of 109 cases. World J Surg. 2014;38:660–6.
Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984;199:461–6.
Brose M, Nutting C, Jarzab B, Elisei R, Sieno S, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind phase 3 trial. Lancet. 2014;384:319–28.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.
Berdelou A, Borget I, Godbert Y, Nguyen T, Garcia ME, Chougnet CN, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid. 2018;28(1):72–8.
Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer. 2019;118:35–40.
Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, et al. Lenvatinib in advanced radioiodine-refractory thyroid cancer - a retrospective analysis of the Swiss lenvatinib named patient program. J Cancer. 2018;9:250–5.
Ito Y, Miyauchi A, Ito M, Yabuta T, Masuoka H, Higashiyama T, et al. Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy. Endocr J. 2014;61:821–4.
Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Prognostic significance of young age in papillary thyroid carcinoma: analysis of 5733 patients with 150 months’ median follow-up. Endocr J. 2014;61:491–7.
Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16.
Miyauchi A, Kudo T, Kihara M, Higashiyama T, Ito Y, Kobayashi K, et al. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J. 2013;60:415–21.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.
Miyauchi A, Kudo T, Hirokawa M, Ito Y, Kihara M, Higashiyama T, et al. Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J. 2013;2:57–64.
Sabra MM, Sherman EJ, Tuttle RM. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer. 2017;123:2955–64.
Tuttle M, Morris L, Haugen B, Shah J, Sosa J, Rohren E, et al. Thyroid-differentiated and anaplastic carcinoma (Chapter 73). In: Amin MB, Edge SB, Greene F, Byrd D, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley J, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2017.
Ito M, Miyauchi A, Morita S, Kudo T, Nishihara E, Kihara M, Takamura Y, Ito Y, Kobayashi K, Miya A, Kubota S, Amino N. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol. 2012;167:373–8.
Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5768 patients with average 10-year follow-up. World J Surg. 2012;36:1274–8.
Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016;101:4103–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ito, Y., Miyauchi, A. (2021). A Patient with Papillary Thyroid Carcinoma and Biochemical Evidence of Disease at Follow-Up Visits and Increasing Serum Tg Values at Follow-Up Assessments. In: Grani, G., Cooper, D.S., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-61919-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-61919-0_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-61918-3
Online ISBN: 978-3-030-61919-0
eBook Packages: MedicineMedicine (R0)